Gojanovic Boris, Feihl François, Liaudet Lucas, Waeber Bernard
Division of Clinical Pathophysiology, Centre Hospitalier Universitaire Vaudois et Université de Lausanne, Lausanne, Switzerland.
J Renin Angiotensin Aldosterone Syst. 2008 Mar;9(1):1-9. doi: 10.3317/jraas.2008.007.
Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists (CAs) and blockers of the renin-angiotensin system [angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists (ARBs)] are widely used today to initiate antihypertensive treatment but, when given as monotherapy, do not suffice in most patients to normalise blood pressure (BP). Combining a CA and either an ACE-inhibitor or an ARB considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. Several fixed-dose combinations are available (CA + ACE-inhibitors: amlodipine + benazepril, felodipine + ramipril, verapamil + trandolapril; CA + ARB: amlodipine + valsartan). They are expected not only to improve BP control, but also to facilitate long-term adherence with antihypertensive therapy, thereby providing maximal protection against the cardiovascular and renal damage caused by high BP.
高血压的药物治疗对于预防心血管和肾脏并发症是有效的。钙拮抗剂（CAs）和肾素-血管紧张素系统阻滞剂[血管紧张素转换酶（ACE）抑制剂和血管紧张素II拮抗剂（ARBs）]如今被广泛用于启动抗高血压治疗，但是，当作为单一疗法使用时，在大多数患者中并不足以使血压（BP）恢复正常。联合使用一种钙拮抗剂和一种ACE抑制剂或一种ARB可显著提高抗高血压疗效，但不会以耐受性恶化为代价。有几种固定剂量复方制剂可供使用（钙拮抗剂+ACE抑制剂：氨氯地平+贝那普利、非洛地平+雷米普利、维拉帕米+群多普利；钙拮抗剂+ARB：氨氯地平+缬沙坦）。预期它们不仅能改善血压控制，还能促进长期坚持抗高血压治疗，从而为高血压所致的心血管和肾脏损害提供最大程度的保护。
